WO2013011526A1 - Procédé de préparation de la lisdexamphétamine et de ses sels - Google Patents

Procédé de préparation de la lisdexamphétamine et de ses sels Download PDF

Info

Publication number
WO2013011526A1
WO2013011526A1 PCT/IN2012/000506 IN2012000506W WO2013011526A1 WO 2013011526 A1 WO2013011526 A1 WO 2013011526A1 IN 2012000506 W IN2012000506 W IN 2012000506W WO 2013011526 A1 WO2013011526 A1 WO 2013011526A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
methyl
diamino
solvent
protected
Prior art date
Application number
PCT/IN2012/000506
Other languages
English (en)
Inventor
Shekhar Bhaskar Bhirud
Singh Sarin Gurdeep
Rajiv Kumar
Original Assignee
Ind-Swift Laboratories Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ind-Swift Laboratories Limited filed Critical Ind-Swift Laboratories Limited
Publication of WO2013011526A1 publication Critical patent/WO2013011526A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/04—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups from amines with formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/12—Preparation of carboxylic acid amides by reactions not involving the formation of carboxamide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/06—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups by reactions not involving the formation of carbamate groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C269/00—Preparation of derivatives of carbamic acid, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C269/08—Separation; Purification; Stabilisation; Use of additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
    • C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C303/00—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides
    • C07C303/02—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof
    • C07C303/22—Preparation of esters or amides of sulfuric acids; Preparation of sulfonic acids or of their esters, halides, anhydrides or amides of sulfonic acids or halides thereof from sulfonic acids, by reactions not involving the formation of sulfo or halosulfonyl groups; from sulfonic halides by reactions not involving the formation of halosulfonyl groups

Definitions

  • the present invention relates to an industrial advantageous process for preparation of pure amphetamine prodrug, in particular, lisdexamphetamine and its pharmaceutically acceptable salts. Further the present invention relates to a novel process for purification of diamino protected intermediate, chemically named as [5-tert-butoxycarbonylamino-5-(l-methyl-2- phenyl-ethylcarbamoyl)-pentyl]-carbamic acid tert-butyl ester, a key intermediate in preparation of lisdexamphetamine.
  • Lisdexamphetamine of formula I is a conjugate of D-amphetamine and L-lysine and is chemically named as (2S)-2,6-diamino-N-[(lS)-methyl-2-phenylethyl]hexan amide.
  • Amphetamines stimulate central nervous system (CNS). Amphetamine is prescribed for treatment of various disorders, including attention deficit hyperactivity disorder (ADHD), obesity, nacrolepsy. It is approved as lisdextamphetamine dimesylate of formula IA and
  • Vyvanse for treatment of attention-deficit hyperactivity disorder in pediatric patients.
  • L-Lysine-D-amphetamine and its pharmaceutically acceptable salts were first disclosed in US patent 7,662,787 wherein it is exemplified as hydrochloride salt.
  • Process for preparation of L- lysine-D-amphetamine includes reaction of BOC-Lys-(BOC)-hydroxysuccinimido ester with D-amphetamine in dioxane using diisopropyl ethyl amine (DIPEA) as a base to obtain BOC- protected lisdexamphetamine which is then purified using flash chromatography and further reacted with a mixture of 4M hydrochloric acid /dioxane to yield L-lysine-D-amphetamine hydrochloride.
  • DIPEA diisopropyl ethyl amine
  • Process includes preparation of BOC-Lys-(BOC)-hydroxysuccinimido ester wherein use of reagents like N-hydroxy-succinimide (NHS) and ⁇ , ⁇ -dicyclohexyl- carbodimiide (DCC) is carried out,
  • reagents like N-hydroxy-succinimide (NHS) and ⁇ , ⁇ -dicyclohexyl- carbodimiide (DCC) is carried out
  • ⁇ , ⁇ -dicyclohexylcarbodimiide is known to be highly toxic and moisture sensitive compound, and its use leads to formation of a large amount of ⁇ , ⁇ -dicyclohexyl urea (DCU) as bye product which has to be removed from reaction mixture.. Therefore use of DCC is not advisable at industrial scale.
  • DCU ⁇ , ⁇ -dicyclohexyl urea
  • alkylphosphonic acid anhydrides which are expensive, and needs additional testing to show absence of phosphic impurities in intermediate or final compound to meet regulatory requirements. So it is not appealing to use alkylphosphonic anhydrides for scale up operations.
  • the principle objective of present invention is to provide an industrially advantageous and efficient process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts.
  • Another objective of present invention is to provide a novel process for purification of diamino protected intermediate . commonly called as BOC protected lisdexamphetamine, by simple crystallization.
  • Yet another objective of the present invention is to provide a process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts using novel mixed anhydride intermediate.
  • Yet another objective of the present invention is to provide a novel mixed anhydride intermediate.
  • the present invention provides an improved and industrially advantageous process for preparation of highly pure lisdexamphetamine of formula I and its pharmaceutically acceptable salts.
  • present invention provides a process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts of formula I, which comprises steps of :
  • R can be selected from alkyl or aryl groups such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, n-pentyl, isopentyl, phenyl, substituted phenyl, where the phenyl group is substituted by 4-methyl, 4-chloro,4- bromo, 4-iodo, 4-nitro, benzyl,, substituted benzyl, where benzyl is substituted by 4-methyl, 4-nitro, 4-chloro, 4- bromo, 4-iodo; .and X is halogen selected from chloro, bromo or iodo.,
  • the present invention provides a novel process for purification of diamino protected amide compound of formula VI, which comprises:
  • the present invention provides a process of preparation of diamino protected amide compound of formula VI which comprises:
  • the present invention provides a process for preparation of lisdexamphetamine and its pharmaceutically acceptable salts of formula I, from L-lysine in one pot without isolating intermediates.
  • the present invention provides a novel mixed anhydride intermediate of formula IV Formula IV
  • R and PG are same as defined above.
  • the present invention provides an improved and industrially advantageous process for preparation of highly pure lisdexamphetamine and its pharmaceutically acceptable salts of formula I.
  • One embodiment of the present invention provides a process for the preparation of lisdexamphetamine of formula I and its pharmaceutically acceptable salt thereof, starting from reacting L-lysine monohydrochloride with amine protecting group using base and a solvent to give diamino protected L-lysine compound of Formula II
  • PG is a nitrogen protecting group
  • Amine protecting group may be selected from any group which is suitable to protect amine group.
  • suitable amine protecting group includes, but not limited to t- butyloxycarbonyl (BOC), benzyloxycarbonyl(CBz), allyloxycarbonyl (,Alloc) fluorenyl methyloxycarbonyl (Fmoc), trimethylsilylethyloxycarbonyl (Teoc), pivaloyl, trifluoro acetyl etc.
  • the amine protecting group is t-butyloxycarbonyl(BOC).
  • Base can be selected from alkali or alkaline metal hydroxides, carbonates, alkoxides and hydrides, for example sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, sodium methoxide, potassium methoxide, sodium hydride, potassium hydride, lithium hydride and the like, preferably the base used is sodium or potassium hydroxide.
  • Solvent can be selected from a group consisting of water or water miscible solvents like ethanol, methanol, n-propyl alcohol, isopropyl alcohol, tetrahydrofuran, N,N-dimethyl- formamide, ⁇ , ⁇ -dimethylacetamide, dimethylsulfoxide, acetonitrile, propionitrile, acetone, ethyl methyl ketone, diethyl ketone and mixture thereof.
  • solvent used for the reaction is water.
  • the reaction is generally performed at temperature range of 0°C to 80°C for a few minutes to few hours, especially between 5°C to 35°C during addition of ditertiary butyl dicarbonate. Further reaction temperature can be raised 40°C to 70°C and reaction mass is maintained at this tepretaure for 12 to 15 hours or till completion of the reaction. The completion of reaction can be monitored by suitable chromatographic technique such as high pressure liquid chromatography (HPLC) or thin layer chromatography (TLC).
  • HPLC high pressure liquid chromatography
  • TLC thin layer chromatography
  • the next phase of synthetic procedure involves carboxylic acid group activation of diamino protected L-lysine compound of formula II by using acid activating reagent of formula III in the presence of a suitable base and a solvent to give
  • R and PG are same as defined above.
  • Acid activating reagent can be selected from a group consisting of haloformate such as methyl chloroformate, ethyl chloroformate, n-propyl chloroformate, isopropyl chloroformate, isobutyl chloroformate, benzyl chloroformate, phenyl chloroformate, aryloxy chloroformate, benzyloxy chloroformate and like thereof.
  • acid activating reagent used is isobutyl chloroformate.
  • Base used for carboxylic acid group activation reaction can be selected from organic base such as alkyl amine and includes but not limited to triethyl amine, di-isopropyl ethyl amine, tri-n-propyl amine, tri-n-butyl amine, pyridine, lutidine and like thereof.
  • the base used is triethyl amine or di-isopropyl ethyl amine.
  • Solvent used for carboxylic acid group activation and subsequent reactions can be selected from C 5-8 aliphatic or aromatic hydrocarbons such as n-pentane, n-hexane, n-heptane, cyclopentane, cyclohexane, cycloheptane, toluene, xylene; C halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane; C 3-6 esters such as methyl acetate, ethyl acetate, n-propyl acetate, isopropyl acetate, n-butyl acetate, isobutyl acetate and like; C 4 .
  • C 5-8 aliphatic or aromatic hydrocarbons such as n-pentane, n-hexane, n-heptane, cyclopentane, cyclohexane, cycloh
  • ethers such as diethyl ether, di-isopropyl ether, methyl t-butyl ether, 1,2-dimethoxy ethane, 1,2-diethoxy ethane, tetrahydrofuran, 2-methyl tetrahydrofuran and dioxane; C 3-6 ketones such as acetone, methyl ethyl ketone, diethyl ketone, methyl isobutyl ketone, and alkylnitriles such as acetonitrile, propionitrile and amides such as N,N- dimethylformamide, ⁇ , ⁇ -dimethyl acetamide; sulfoxide such as dimethyl sulfoxide and mixture thereof.
  • solvent used for the reaction is dichloromethane.
  • Carboxylic acid group activation reaction is conducted at a temperature of -30°C to 35°C for 5 to 180 minutes. Preferably reaction is carried out at a temperature of -20°C to 20°C for 60 to 120 minutes or till the completion of the reaction.
  • the reaction completion can be monitored by thin layer chromatography (TLC) or high pressure liquid chromatography (HPLC).
  • reaction of mixed anhydride intermediate of formula IV with D-amphetamine of formula V or salt thereof is conducted at a temperature of -30°C to 50°C for 30 to 180 minutes.
  • reaction is performed at a temperature of -20°C to 30°C for 60 to 120 minutes or till the completion of the reaction.
  • diamino protected amide compound of formula VI is converted to lisdexamphetamine of formula I or its pharmaceutically acceptable salts.
  • diamino protected amide compound of formula VI can be purified to enhance purity.
  • HPLC analysis indicates the presence of impurities like l,3-bis(l-methyl-2-phenyethyl)urea of formula VII and (1- methyl-2-phenylethyl)carbamic acid isobutyl ester of formula VIII as shown below:
  • Crude diamino protected amide compound of formula VI may have purity 85 to 95% by HPLC
  • the present invention involves a novel process for purification of diamino protected amide compound of formula VI by simple technique to remove the impurities of formula VII and VIII which comprises dissolving crude diamino protected amide compound of formula VI having purity between 85% to 95% (by HPLC) in a suitable solvent selected from the group consisting of Ci -5 alcohols such as methanol, ethanol, n-propanol, isopropanol, n-butanol, isobutanol; halogenated solvents such as dichloromethane, chloroform, carbon tetrachloride, 1,2-dichloroethane; ethers such as dimethyl ether, diethyl ether, diisopropyl ether, methyl tertiary butyl ether, tetrahydrofuran, 2- methyl tetrahydrofuran, 1,2-dimethoxy ethane, 1,2-diethoxy ethane, C3 -6 aliphatic
  • antisolvent is added slowly to precipitate the compound.
  • the antisolvent can be selected from water; hydrocarbon such as n-pentane, n-hexane, hexanes, n-heptane, heptanes, cyclohexane, cycloheptane, toluene, 1,2 and 1,4-xylene; alkyl nitriles such as acetonitrile, propionitrile; aliphatic ethers such as diethyl ether, isopropyl ether, methyl tertiary butyl ether and mixture thereof , preferably antisolvent used is water.
  • Diamino protected amide compound of formula VI obtained by the described purification may have a purity of not less than 99 % by HPLC, more preferably not less than 99.5 % and even more preferably not less than 99.9 % by HPLC.
  • Diamino protected compound of formula VI obtained by the described purification process may contain very little amount of impurities of formula VII and VIII not more than 0.2 % and 0.5 %, preferably not more than about 0.05% each by HPLC of diamino protected amide compound of formula VI.
  • Diamino protected amide compound of formula VI can be deprotected by any of the methods known in the prior art to give lisdexamphetamine or its pharmaceutically acceptable salt of formula 1 by using a suitable acid.
  • a suitable acid can be selected from the group consisting of methane sulphonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, ortho phosphoric acid and like thereof. Acid used for deprotection depends on the amine protecting group.
  • Solvent used for reaction can be selected from water; C 1-5 alcohols such as methanol, ethanol, n-propanol, isopropyl alcohol, n-butanol, isobutanol, n-pentanol; C4 -8 aliphatic hydrocarbons or aromatic hydrocarbons such as n-pentane, n-hexane, n-heptane; benzene, toluene, 1,2 and 1,4-xylene; C 1-4 halogenated hydrocarbons such as dichloromethane, chloroform, carbon tetrachloride, 1.2-dichloroethane; C 3-6 esters such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate; C 3- 5 ethers diethyl ether, diisopropyl ether, t-butyl methyl
  • the deprotection reaction of diamino protected amide compound of formula VI is carried at a temperature of 5°C to 140°C and for 5 to 12 hours, preferably at a temperature of 15°C to 80°C for 8 to 12 hours or till the completion of the reaction.
  • the reaction completion can be monitored by thin layer chromatography (TLC) or high pressure liquid chromatography (HPLC).
  • TLC thin layer chromatography
  • HPLC high pressure liquid chromatography
  • the product can be isolated by any standard method known in the art such as by filtration, centrifugation or decantation. Typically the product is isolated by filtration in laboratory on small scale & by centrifuging on commercial scale.
  • lisdexamphetamine and its pharmaceutically acceptable salts of formula I can be prepared by one pot process without isolating intermediates.
  • the process comprises of reacting L-lysine monohydrochloride with amine protecting group in presence of base and a solvent to give diamino protected L-lysine compound of Formula II.
  • Base can be selected from alkali or alkaline metal hydroxides, carbonates, alkoxides and hydrides, for example sodium hydroxide, potassium hydroxide, calcium hydroxide, lithium hydroxide, sodium carbonate, potassium carbonate, calcium carbonate, sodium methoxide, potassium methoxide, sodium hydride, potassium hydride, lithium hydride and the like, preferably the base used is sodium or potassium hydroxide.
  • Solvent can be selected from the group consisting of water or water miscible solvents as described earlier. Preferably solvent used for the reaction is water.
  • reaction is generally performed at temperature range of 0°C to 80°C for a few minutes to few hours, especially between 5°C to 35°C during addition of ditertbutyl dicarbonate and then in temperature range of40°C to 70°C for 12 to 15 hours or till completion of the reaction.
  • the reaction completion can be monitored by suitable chromatographic techniques such as HPLC or TLC.
  • reaction mixture is cooled to 20°C to 30°C.
  • Water is added to the reaction mixture and further extracted with a suitable water immiscible solvent preferably methylene dichloride. Thereafter pH of aqueous layer is adjusted between 2 to 5, preferably 2.5 to 3.5 by using a suitable acid.
  • product is extracted from the aqueous layer using suitable water immiscible solvent.
  • Solvent for extraction includes halogenated solvents such as dichloromethane, 1,2-dichloroethane, chloroform, carbon tetrachloride, esters such as methyl acetate, ethyl acetate, propyl acetate or the like.
  • Suitable acid includes hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, acetic acid, formic acid and the like.
  • Organic layer can be washed with water and sodium chloride solution. Organic layer is dried using sodium sulfate. Organic layer having diamino protected L-lysine compound of Formula II is reacted with acid activating reagent of formula III in presence of a base in a solvent to form mixed anhydride intermediate of formula IV which is further reacted with D-amphetamine of formula V to form diamino protected compound of formula VI.
  • Acid activating reagent can be selected from the group consisting of haloformate such as methyl chloroformate, ethyl chloroformate, n-propyl chloroformate, isopropyl chloroformate, isobutyl chloroformate, benzyl chloroformate, phenyl chloroformate, aryloxy chloroformate, benzyloxy chloroformate and like thereof.
  • acid activating reagent used is isobutyl chloroformate.
  • Base used for carboxylic acid group activation reaction can be selected from triethyl amine, di-isopropyl ethyl amine, tri-n-propyl amine, tri-n-butyl amine, pyridine, lutidine and like.
  • base is triethyl amine or di-isopropyl ethyl amine.
  • Carboxylic acid group activation reaction is conducted at a temperature of -30°C to 35°C for 5 to 180 minutes.
  • reaction is carried out at a temperature of -20°C to 20°C for 60 to 120 minutes or till the completion of the reaction.
  • the reaction completion can be monitor by TLC or HPLC or UPLC.
  • the reaction of mixed anhydride intermediate of formula IV with D-amphetamine of formula V is conducted at a temperature of -30°C to 50°C for 30 to 180 minutes. Preferably at a temperature of -20°C to 30°C for 60 to 120 minutes.
  • reaction mixture is successively washed with dilute hydrochloric acid, sodium bicarbonate solution, water and sodium chloride solution followed by distillation of organic layer to afford a residue , which is treated with a suitable acid to obtain lisdexamphetamine or its pharmaceutically acceptable salt of formula 1.
  • a suitable solvent is added and then solution is treated with suitable acid.
  • Solvent used for the reaction can be selected from water; C 1-5 alcohols C 4-8 aliphatic hydrocarbons or aromatic hydrocarbons C 1-4 halogenated hydrocarbons; C 3-6 esters; C 3-5 ethers, 1,2-dimethoxy ethane, 1,2-diethyoxy ethane, tetrahydrofuran, 2-methyl tetrahydrofuran and dioxane; C 3-6 ketones and nitriles or mixture thereof, as described above.
  • Suitable acid can be selected from the group consisting of methane sulphonic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, nitric acid, ortho phosphoric acid and like thereof. Acid used for deprotection depends on the amine protecting group.
  • the deprotection reaction can be carried out at a temperature of 5°C to 140°C and it takes 5 to 12 hours for completion of reaction.
  • the reaction completion can be monitored by TLC or HPLC.
  • the product can be isolated by any standard method known in the art Typically product is isolated by filtration.
  • the product isolated can optionally be purified to enhance purity if required.
  • a suitable solvent selected from a group consisting of C[. 6 alcohols such as methanol, ethanol, n-propanol, isopropanol n-butanol, isobutanol, n-pentanol, isopentanol, hexanol; preferably solvent used is ethanol, at a temperature of 10 to 70°C, preferably at 50 to 60°C to get a clear solution then add antisolvent selected from C 3 _6 esters such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate; C 3 .
  • aliphatic ketones such as acetone, diethyl ketone, diisopropyl ketone, ethyl methyl ketone, methyl isobutyl ketone; alkyl nitrile such as acetonitrile and propionitrile; preferably antisolvent used is ethylacetate, at a temperature of 30°C to 70°C, preferably at 50°C to 60°C.
  • the reaction mixture is cooled to -10°C to 40°C, preferably at 20°C to 30°C. Stirring is conducted for 20 minutes to 24 hours, preferably for 30 to 120 minutes, more preferably till complete precipitation.
  • the product can be isolated by any standard method known in the art such as by filtration, centrifugation or decantation. Typically the product is isolated by filtration.
  • the purity of lisdexamphetamine and its pharmaceutically acceptable salt obtained by the present invention is more than 99 %, preferably more than 99.5 %, more preferably more than 99.7 %, which may be further purified by using simple process to get purity of more than 99.7 %, preferably more than 99.9 %.
  • Lisdexamphetamine and its pharmaceutically acceptable salt can be purified by using simple technique which comprises dissolving crude lisdexamphetamine and its pharmaceutically acceptable salt of formula I having purity between 99% to 99.7% in a suitable solvent selected from the group consisting of C 1-6 alcohols such as methanol, ethanol, n-propanol, isopropanol n-butanol, isobutanol, n-pentanol, isopentanol, hexanol; preferably solvent used is ethanol, at a temperature of 10 to 70°C, preferably at 50 to 60°C to get a clear solution then add antisolvent selected from C 3- 6 esters such as methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, isobutyl acetate; C 3-6 aliphatic ketones such as acetone, diethyl ketone, diisoprop
  • the reaction mixture is cooled to -10°C to 40°C, preferably at 20°C to 30°C. Stirring is conducted for 20 minutes to 24 hours, preferably for 30 to 120 minutes, more preferably till complete precipitation.
  • the product can be isolated by any standard method known in the art such as by filtration, centrifugation or decantation. Typically the product is isolated by filtration.
  • Lisdexamphetamine and pharmaceutically acceptable salt obtained by the present invention may be crystalline or amorphous form. Desired form can be obtained by modification in reaction conditions such as temperature, solvent, time and speed for stirring, temperature of precipitation and rate and time of cooling etc. speed for stirring and rate of cooling etc speed for stirring and rate of cooling etc speed for stirring and rate of cooling etc speed for stirring and rate of cooling etc speed for stirring and rate of cooling etc speed for stirring and rate of cooling etc speed for stirring and rate of cooling etc etc. According to another embodiment, the present invention provides a mixed anhydride intermediate of formula IV
  • amide compound of formula VI is preferably amide compound of formula VI A as represented below:
  • amide compound of formula VI A is prepared by starting from L-lysine monohydrochloride.
  • L-Lysine monohydrochloride is reacted with amine protecting group such as t-butyloxycarbonyl (BOC) using a base and a solvent to give di Boc amino protected
  • Base can be selected from alkali or alkaline metal hydroxides, carbonates, alkoxides and hydrides, as desribed above and preferably base used is sodium or potassium hydroxide.
  • Solvent can be selected from group consisting of water or water miscible solvents like ethanol, methanol, n-propyl alcohol, isopropyl alcohol, tetrahydrofuran, N,N-dimethyl- formamide, ⁇ , ⁇ -dimethylacetamide, dimethylsulfoxide, acetonitrile, propionitrile, acetone, ethyl methyl ketone, diethyl ketone and mixture thereof.
  • solvent used for the reaction is water.
  • the reaction is generally performed at temperature range of 0°C to 80°C for a few minutes to few hours, especially between 5°C to 35°C during addition of ditertiary butyl dicarbonate. Further reaction temperature can be raised 40°C to 70°C and reaction mass is maintained at this temperature for 12 to 15 hours or till completion of the reaction. The completion of reaction can be monitored by suitable chromatographic technique such as HPLC or TLC.
  • the next phase of synthetic procedure involves carboxylic acid group activation of diboc protected L-lysine compound of formula IIA by using isobutyl chloroformate as acid activating reagent, in the presence of a suitable base and a solvent to give a mixed anhydride intermediate of formula IV A
  • Base used for activation reaction can be selected from organic base such as alkyl amine and includes but not limited to triethyl amine, di-isopropyl ethyl amine, tri-n-propyl amine, tri-n- butyl amine, pyridine, lutidine and like thereof.
  • the base used is triethyl amine or di-isopropyl ethyl amine.
  • Solvent used for activation reaction can be selected from Cs. 8 aliphatic or aromatic hydrocarbons; C 1-4 halogenated hydrocarbons; C 3- esters; C 4-8 ethers; C 3 . ketones, alkylnitriles; amides; sulfoxide and mixture thereof as described above.
  • solvent used for the reaction is dichloromethane.
  • Activation reaction is conducted at a temperature of -30°C to 35°C for 5 to 180 minutes. Preferably reaction is carried out at a temperature of -20°C to 20°C for 60 to 120 minutes or till the completion of the reaction. The reaction completion can be monitored by TLC or HPLC.
  • the mixed anhydride intermediate of formula IV A is further reacted with D- amphetamine of formula V or salt thereof to prepare diBOC amino protected compound of formula VIA, which is isolated and converted to lisdexamphetamine and its pharmaceutically acceptable salts of formula I.
  • Major advantages realized in the present invention are cost effectiveness and efficiency of process which can be easily and conveniently scaled-up for industrial large scale production.
  • the process is simple, economical, operationally efficient, high through output, and provides lisdexamphetamine and its pharmaceutically acceptable salts in high yield and purity without using expensive reagents.
  • Another advantage of this process is that it involves one pot preparation of lisdexamphetamine mesylate without isolation of intermediate at various stages avoiding lengthy separation process arid purification of intermediates, which in turn saves time, resources and hence increases the yield of desired compound.
  • Example 2 Preparation of (5-tert-butoxycarbonylamino-5-(l-methyl-2-phenyl- ethylcarba moyl)-pentyll-carbamic acid tert-butyl ester;
  • reaction temperature was raised to 25-30°C and reaction mixture was successively washed with 0.5 N hydrochloric acid solution (2 x 75 ml), sodium bicarbonate solution (5%w/w 75ml), water (50 ml) and brine solution (50 ml).
  • the combined dichloromethane layer was dried over sodium sulfate (10.0 g) and distilled at 30- 40°C to obtain a semisolid compound which was stirred with a mixture of n-heptane (85 ml) and ethyl acetate (5ml) at 25-30°C for 30 minutes. The solid, thus obtained, was filtered and dried to get 10.21 g of title compound having purity 89.77% by HPLC.
  • Lisdexamphetamine dimesylate (1.40g,) was dissolved in ethanol (10 ml) at 50-55 °C and ethyl acetate (10 ml) was slowly added at 50-55 °C. The reaction mixture was cooled to 20- 25°C and stirred for 30 minutes. The resulting solid was filtered, washed with a mixture of ethanol and ethyl acetate (3 ml, 1: 1) and dried under vacuum at 55-60°C to obtain 1.28g of pure lisdexamphetamine dimesylate as a white crystalline solid having purity 99.90 % by HPLC.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La présente invention concerne un procédé amélioré, efficace, sûr et adapté pour la préparation de la lisdexamphétamine et de ses sels pharmaceutiquement acceptables, à l'aide d'un nouvel intermédiaire anhydride mixte. La présente invention concerne également un procédé de préparation d'un composé amide à protection diamino, à savoir la lisdexamphétamine à protection BOC, un intermédiaire clé dans la préparation de la lisdexamphétamine et de ses sels pharmaceutiquement acceptables, à l'aide d'un nouvel intermédiaire anhydride mixte, et sa purification par cristallisation. En outre, l'invention concerne un nouvel intermédiaire anhydride mixte.
PCT/IN2012/000506 2011-07-20 2012-07-18 Procédé de préparation de la lisdexamphétamine et de ses sels WO2013011526A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN2040DE2011 2011-07-20
IN2040/DEL/2011 2011-07-20

Publications (1)

Publication Number Publication Date
WO2013011526A1 true WO2013011526A1 (fr) 2013-01-24

Family

ID=47557744

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2012/000506 WO2013011526A1 (fr) 2011-07-20 2012-07-18 Procédé de préparation de la lisdexamphétamine et de ses sels

Country Status (1)

Country Link
WO (1) WO2013011526A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098533A3 (fr) * 2015-12-11 2017-08-10 Sun Pharmaceutical Industries Limited Procédé de préparation de lisdexamphétamine
US20190161435A1 (en) * 2017-11-30 2019-05-30 SpecGx LLC Process for preparing acylated amphetamine derivatives
EP4122914A1 (fr) 2021-07-22 2023-01-25 SCI Pharmtech Inc. Composé et procédé de préparation de lisdexamfétamine
US11608312B1 (en) 2021-07-22 2023-03-21 Sci Pharmtech Inc. Compound and method for preparation of lisdexamfetamine
WO2024003797A1 (fr) * 2022-06-30 2024-01-04 Ind-Swift Laboratories Limited Sels cristallins de lisdexamfétamine

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080086016A1 (en) * 2003-05-29 2008-04-10 New River Pharmaceuticals Inc. Abuse resistant lysine amphetamine compounds
WO2010042120A1 (fr) * 2008-10-09 2010-04-15 Archimica, Inc. Procédé pour la synthèse de dérivés d’amphétamine
WO2010148305A1 (fr) * 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Procédés et compositions pour la préparation de conjugués d'amphétamine et de sels de ceux-ci

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080086016A1 (en) * 2003-05-29 2008-04-10 New River Pharmaceuticals Inc. Abuse resistant lysine amphetamine compounds
WO2010042120A1 (fr) * 2008-10-09 2010-04-15 Archimica, Inc. Procédé pour la synthèse de dérivés d’amphétamine
WO2010148305A1 (fr) * 2009-06-19 2010-12-23 Cambrex Charles City, Inc. Procédés et compositions pour la préparation de conjugués d'amphétamine et de sels de ceux-ci

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017098533A3 (fr) * 2015-12-11 2017-08-10 Sun Pharmaceutical Industries Limited Procédé de préparation de lisdexamphétamine
US20190161435A1 (en) * 2017-11-30 2019-05-30 SpecGx LLC Process for preparing acylated amphetamine derivatives
JP2021504324A (ja) * 2017-11-30 2021-02-15 スペックジーエックス エルエルシー アシル化アンフェタミン誘導体を調製するためのプロセス
US10927068B2 (en) * 2017-11-30 2021-02-23 SpecGx LLC Process for preparing acylated amphetamine derivatives
JP7263350B2 (ja) 2017-11-30 2023-04-24 スペックジーエックス エルエルシー アシル化アンフェタミン誘導体を調製するためのプロセス
AU2018374838B2 (en) * 2017-11-30 2023-10-05 SpecGx LLC Process for preparing acylated amphetamine derivatives
EP4122914A1 (fr) 2021-07-22 2023-01-25 SCI Pharmtech Inc. Composé et procédé de préparation de lisdexamfétamine
US11608312B1 (en) 2021-07-22 2023-03-21 Sci Pharmtech Inc. Compound and method for preparation of lisdexamfetamine
EP4215517A1 (fr) 2021-07-22 2023-07-26 SCI Pharmtech Inc. Composé et procédé de préparation de lisdexampefamine
WO2024003797A1 (fr) * 2022-06-30 2024-01-04 Ind-Swift Laboratories Limited Sels cristallins de lisdexamfétamine

Similar Documents

Publication Publication Date Title
US8907132B2 (en) Process for preparing (R)-2-acetamido-N-benzyl-3-methoxy-propionamide
US8759582B2 (en) Process for the preparation of lacosamide
WO2013011526A1 (fr) Procédé de préparation de la lisdexamphétamine et de ses sels
US20130123537A1 (en) Process for the preparation of lacosamide
JP2818763B2 (ja) Ｎ−（ヒドロキシ）アラルキルフェニルエタノールアミン類のｏ−アルキル化された化合物
WO2013072933A2 (fr) Procédé de préparation de 2-acétamido-n-benzyl-3-méthoxypropionamide
US20100113821A1 (en) Preparation of 3-amino-3-(cyclobutylmethyl)-2-(hydroxy)-propionamide hydrochloride
US20110319649A1 (en) Intermediate for producing lacosamide and a process for its preparation and conversion to lacosamide
JP4594938B2 (ja) ガバペンチンの調製方法
US7943784B2 (en) Process for the preparation of almotriptan
US6599922B2 (en) Process for the preparation of 2,5-bis-(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide (FLECAINIDE)
JP5704763B2 (ja) トランス−４−アミノシクロペンタ−２−エン−１−カルボン酸誘導体の製造
JP2013508397A (ja) 高分子化合物の調製方法
JP2004175703A (ja) Ｎ−アルコキシカルボニル−ｔｅｒｔ−ロイシンの製造方法
KR100880623B1 (ko) 발사르탄의 제조방법
CN112272665A (zh) 制备立他司特的方法
JP4147022B2 (ja) Ｎ−アルコキシカルボニル−ｔｅｒｔ−ロイシンの回収方法
WO2004037772A1 (fr) Synthese pratique et modifiable de l'ethyl n-[(2-boc-amino) ethyl] glycinate et de son chlorhydrate
RU2363695C2 (ru) Способ получения периндоприла с использованием тетраметилурониевых солей в качестве реагентов реакции сочетания
JPS61129159A (ja) 保護化アミノ酸アミド化合物の精製法
JP2004238322A (ja) （ｒ）−３−アミノペンタンニトリルメタンスルホン酸塩の製造方法
JP5982720B2 (ja) 高分子固体状支持体を用いたヒスチジル−プロリンアミド誘導体の製造方法
JP2016013977A (ja) ｔｒａｎｓ−１，２−ジアミノシクロヘキサンの製造方法
JPH01104034A (ja) Ｎ↑２−（１−カルボキシ−３−フエニルプロピル）−ｌ−リジン誘導体の製造法
EP2152697A2 (fr) Procédé de préparation de l'alfuzosine et de ses sels

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12815502

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12815502

Country of ref document: EP

Kind code of ref document: A1